Leng Shumei August 24, 2021
An institute in Wuhan, under the China National Biotec Group (CNBG), a subsidiary of Sinopharm, has isolated the Delta variant of the novel coronavirus and is accelerating development on Delta-specific vaccines, its director told the media. The new Delta variant spread to Wuhan after about a year of...More
The world's first trial results on minors aged 3-17 showed China's inactivated COVID-19 vaccine produced by Sinovac had good safety, tolerability, and immunogenicity in youths aged 3-17 years, the Global Times learnt from Sinovac on Tuesday. Observers believe the results will inspire the ongoing trial of other COVID-19...More